SightfileU.S. market data from official filings
Companies › DRUG
BRIGHT MINDS BIOSCIENCES INC (DRUG)
Institutional ownership, SEC filings and insider activity
Sector: Healthcare & Pharma · SEC CIK 0001827401 · EDGAR filings · Updated 2026-07-02
BRIGHT MINDS BIOSCIENCES INC (DRUG) has 93 institutional managers reporting positions valued at $670.3M per the latest 13F reporting period. SEC filings include an active substantial-doubt (going concern) disclosure per the filings.
Institutional managers
93
Reported 13F value
$670.3M
Data flags
1 active
from SEC filings
Latest updates
- 2026-07-02 — SCHEDULE 13D/A filed
- 2026-06-03 — Foreign issuer report (6-K) filed
- 2026-06-02 — Foreign issuer report (6-K) filed
- 2026-05-28 — Foreign issuer report (6-K) filed
- 2026-05-20 — Foreign issuer report (6-K) filed
- 2026-05-15 — SCHEDULE 13G filed
Institutional ownership overview
According to SEC 13F filings tracked by Sightfile, BRIGHT MINDS BIOSCIENCES INC has 93 institutional holders.
Data flags from SEC filings
Active substantial-doubt (going concern) disclosure per the filings, most recently filed 2024-12-31 (recurring since 2021-12-29) — source filing. The authoritative details are those stated in the filing itself.
Related companies
LB PHARMACEUTICALS INC (LBRX) · KURA ONCOLOGY INC COM (KURA) · CASTLE BIOSCIENCES INC (CSTL) · GH RESEARCH PLC (GHRS) · SPYGLASS PHARMA INC (SGP) · TALKSPACE INC (TALK)
See full history, cross-references and alerts on SightfileSightfile provides information only — not investment advice, recommendations, or an assessment of any security. Data is derived from official public sources (SEC EDGAR and U.S. government agencies), may contain errors or delays, and should be verified against the source filing before relying on it.
Data sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-07-02.
Data sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-07-02.